Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Analysts

Maze Therapeutics, Inc. (NASDAQ:MAZE) has been assigned a consensus rating of “Buy” from the nine brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, six have given a buy rating and two have assigned a strong buy rating to the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $37.00.

Several analysts have issued reports on MAZE shares. Weiss Ratings restated a “sell (d)” rating on shares of Maze Therapeutics in a research report on Wednesday, October 8th. BTIG Research increased their target price on Maze Therapeutics from $30.00 to $37.00 and gave the company a “buy” rating in a report on Friday, September 12th. Guggenheim raised their price target on Maze Therapeutics from $19.00 to $34.00 and gave the stock a “buy” rating in a research report on Monday, September 15th. Wall Street Zen upgraded Maze Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 16th. Finally, JPMorgan Chase & Co. raised their target price on shares of Maze Therapeutics from $27.00 to $37.00 and gave the stock an “overweight” rating in a report on Monday, September 29th.

Maze Therapeutics Trading Down 3.5%

Shares of NASDAQ MAZE opened at $28.60 on Monday. The stock’s 50-day moving average is $25.85 and its 200 day moving average is $17.31. The stock has a market cap of $1.25 billion and a price-to-earnings ratio of -1.37. Maze Therapeutics has a 1-year low of $6.71 and a 1-year high of $34.29.

Maze Therapeutics (NASDAQ:MAZE) last announced its quarterly earnings data on Thursday, November 6th. The company reported ($0.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.08.

Insider Activity

In other Maze Therapeutics news, Director Richard H. Scheller sold 20,744 shares of the business’s stock in a transaction dated Monday, September 15th. The shares were sold at an average price of $22.37, for a total value of $464,043.28. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink.

Hedge Funds Weigh In On Maze Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the stock. TRV GP IV LLC purchased a new stake in Maze Therapeutics in the first quarter worth about $66,874,000. Frazier Life Sciences Management L.P. purchased a new position in shares of Maze Therapeutics in the 1st quarter valued at approximately $45,460,000. ARCH Venture Management LLC bought a new stake in shares of Maze Therapeutics during the first quarter valued at approximately $45,362,000. Matrix Capital Management Company LP purchased a new stake in Maze Therapeutics in the first quarter worth $27,373,000. Finally, Alphabet Inc. bought a new position in Maze Therapeutics in the first quarter worth $26,561,000.

About Maze Therapeutics

We are a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small molecule precision medicines for patients living with renal, cardiovascular and related metabolic diseases, including obesity. We are advancing a pipeline using our Compass platform, which allows us to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process we refer to as variant functionalization.